RestructuringMay 11, 2026, 05:12 PM
Quince Therapeutics Ceases eDSP Development; Going Concern Warning
AI Summary
Quince Therapeutics announced the cessation of clinical development for its lead asset, eDSP, following the failure of its Phase 3 NEAT clinical trial to meet its primary endpoint. This significant setback led management to issue a going concern warning, citing insufficient cash to fund operations for the next twelve months and the need to evaluate strategic alternatives. Despite reporting a net income of $35.9 million for Q1 2026, driven by non-operating fair value adjustments and an intangible asset impairment charge, the company faces substantial operational challenges.
Key Highlights
- Quince Therapeutics ceased eDSP development after Phase 3 NEAT clinical trial failed to meet its primary endpoint.
- Management issued a going concern warning due to insufficient cash to fund operations for the next 12 months.
- Reported Q1 2026 net income of $35.9 million, compared to a $15.0 million net loss in Q1 2025.
- Cash and cash equivalents increased to $18.2 million as of March 31, 2026, from $5.8 million at year-end 2025.
- Recorded a $67.8 million intangible asset impairment charge in Q1 2026 related to eDSP.
- Contingent consideration liability was reduced by $64.3 million to zero due to trial failure.
- Settled the European Investment Bank loan for $5.5 million in March 2026.
- Effected a 1-for-10 reverse stock split on April 10, 2026.